ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have earned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $3.50.

A number of equities research analysts recently commented on ALXO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of ALX Oncology in a report on Wednesday, October 8th. Wall Street Zen raised ALX Oncology from a “sell” rating to a “hold” rating in a research note on Monday, December 22nd. Finally, Jefferies Financial Group initiated coverage on shares of ALX Oncology in a research note on Thursday, November 13th. They set a “buy” rating and a $4.00 price objective on the stock.

Hedge Funds Weigh In On ALX Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bridgeway Capital Management LLC bought a new stake in shares of ALX Oncology in the 3rd quarter valued at $66,000. Invesco Ltd. acquired a new position in ALX Oncology in the first quarter valued at about $46,000. AQR Capital Management LLC increased its holdings in shares of ALX Oncology by 183.6% in the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after acquiring an additional 77,065 shares in the last quarter. Nuveen LLC bought a new stake in shares of ALX Oncology in the first quarter worth about $103,000. Finally, Jane Street Group LLC acquired a new stake in shares of ALX Oncology during the second quarter worth about $84,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Trading Down 5.0%

Shares of NASDAQ ALXO opened at $1.13 on Friday. ALX Oncology has a fifty-two week low of $0.40 and a fifty-two week high of $2.27. The firm has a market capitalization of $61.27 million, a P/E ratio of -0.56 and a beta of 0.51. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.40 and a quick ratio of 2.40. The company’s 50 day simple moving average is $1.41 and its 200 day simple moving average is $1.13.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Friday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04). On average, analysts predict that ALX Oncology will post -2.76 EPS for the current year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.